Autopsy report · NCT02978443

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

“Lack of Enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 5 years before it stopped.
• 14 participants enrolled.
• Results were posted on the registry 1 year 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Georgetown University

Sponsor type

University, hospital or other

Conditions

Acral Lentiginous Melanoma; Mucosal Melanoma

Interventions

Nivolumab; Ipilimumab

Participants

14

Sites

5

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.